1

1	Antibody response to <i>Plasmodium vivax</i> in the context of Epstein-Barr virus		
2	(EBV) co-infection: A 14-year follow-up study in the Amazon rainforest		
3			
4	Luiz F. F. Guimarães ¹ , Bárbara A. Rodrigues ¹ , Michelle H. F. Dias ¹ , Matheus G. Barcelos ² ,		
5	Maria F. A. Nascimento ¹ , Sâmick L. Moreira-Nascimento ¹ , Sofia L. Afonso ¹ , Barbara G. S. Abreu		
6	Jaap. M. Middeldorp ³ , Francis B. Ntumngia ⁴ , John H. Adams ⁴ , Camila Fabbri ^{5,6} , Stefanie Lopes ^{5,}		
7	Cor J. F. Fernandes ⁷ , Flora S. Kano ¹ , Luzia H. Carvalho ^{1*}		
8			
9	¹ Instituto René Rachou, Fiocruz Minas, Fundação Oswaldo Cruz (Fiocruz), Belo Horizonte,		
10	Minas Gerais, Brazil		
11	² Laboratório de vírus, Departamento de Microbiologia, Instituto de Ciências Biológicas,		
12	Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil		
13	³ Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.		
14	⁴ Center for Global Health and Interdisciplinary Disease Research, College of Public Health,		
15	University of South Florida, Tampa, Florida, United States		
16	⁵ Instituto Leônidas & Maria Deane, Fiocruz Amazônia, Fundação Oswaldo Cruz, Manaus,		
17	Amazonas, Brazil		
18	⁶ Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Unidade de Pesquisa Clínica		
19	Carlos Borborema, Manaus, Amazonas, Brazil		
20	⁷ Hospital Universitário Julio Müller, Faculdade de Medicina, Universidade Federal de Mato		
21	Grosso (UFMT), Cuiabá, Mato Grosso, Brazil		
22			
23	*Corresponding author		
24	E-mail: luzia.carvalho@fiocruz.br (LHC)		
25			
26			

27 Abstract

Background: To develop an effective vaccine against *Plasmodium vivax*, the most widely dispersed human malaria parasite, it is critical to understand how coinfections with other pathogens could impact malaria-specific immune response. A recent conceptual study proposed that Epstein-Barr virus (EBV), a highly prevalent human herpesvirus that establishes lifelong persistent infection, may influence *P. vivax* antibody responses. Here, it was investigated whether EBV could impact the longevity of humoral immune response to *P. vivax*.

34 Methodology/principal findings: A 14-year follow-up study was carried out among long-35 term P. vivax-exposed Amazonian individuals (272, median age 35 years), and included 9 cross-36 sectional surveys at periods of high and low malaria transmission. The experimental approach 37 focused on monitoring antibodies to the major blood-stage *P. vivax* vaccine candidate, the Duffy 38 binding protein region II (DBPII-Sal1), including a novel engineered DBPII-based vaccine targeting 39 conserved epitopes (DEKnull-2). In parallel, the status of EBV infection was determined over time 40 by the detection of circulating EBV DNA (EBV-DNAemia) and EBV-specific antibodies to lytic 41 (VCAp18) or latent (EBNA1) antigens. Regardless of the malaria transmission period, the results 42 demonstrated that one or multiple episodes of EBV-DNAemia did not influence the longevity of 43 DBPII immune responses to both strain-specific (Sal-1) or strain-transcending (DEKnull-2) 44 antibodies. Also, the average time in which DBPII-responders lost their antibodies was unrelated to 45 the EBV serostatus. Considering all malaria cases detected during the study, there was a 46 predominance of *P. vivax* mono-infection (76%), with a positive association between malaria 47 infection and detectable EBV-DNAemia.

48 **Conclusions/significance:** In an immunocompetent *P. vivax*-exposed adult population 49 neither sporadic episodes of EBV-DNAemia nor antibody responses to lytic/latent EBV antigens 50 influence the longevity of both strain-specific and strain-transcending DBPII immune responses. 51 Further studies should investigate the role of acute *P. vivax* infection in the activation of EBV 52 replication cycle.

3

53

54 Introduction

55 Despite the decline in the global burden of malaria, the progress towards disease control has 56 stagnated in recent years, underscoring the fragility of hard-won gains against malaria [1]. In the 57 case of *Plasmodium vivax*, the most widespread human malaria parasite, plateauing gains and areas 58 with an increased burden highlight the fact that the challenges on the road to malaria elimination are 59 greater than expected [2]. Key discoveries in *P. vivax* biology, including an endosplenic life cycle 60 associated with recurrent chronic infections, pose additional challenges to control and elimination 61 of the parasite [3, 4]. Concurring, the proportion of malaria caused by *P. vivax* has been increasing 62 in co-endemic regions where intensive malaria-control activities have successfully reduced the 63 incidence of *P. falciparum* [5].

Although under investigated, *P. vivax* in a scenario of co-infection with viruses commonly circulating in endemic areas can worsen the impact of these diseases on public health, reducing the effectiveness of therapeutic and prophylactic measures [6-11]. With continuing interest in the elimination of *P. vivax* infections, and to the development of an effective vaccine against this parasite, it is necessary to understand how viral infections could impact the immune response induced by potential vaccine candidates. Particularly, because there are only a few *P. vivax* vaccines in clinical trials [12].

71 In experimental models, it has been proposed that gamma herpesvirus co-infection with 72 malaria may suppress anti-parasitic humoral immunity [13]. Given that the B-cell compartment is 73 the primary niche for Epstein-Barr virus (EBV), a highly prevalent human gamma herpes virus [14], 74 it is plausible to speculate that the humoral immune response to malaria may be altered during EBV 75 co-infection [13]. In a conceptual case-control study, we provided evidence that antibody levels 76 against major P. vivax vaccine candidates were generally lower in malaria-exposed individuals 77 whose viral DNA was persistently detected in the peripheral blood [15]. To further investigate 78 whether EBV could impact the long-term humoral immune response to *P. vivax*, we took advantage

4

of a 14-year follow-up study among individuals exposed to malaria in the Amazon rainforest,
focusing on a major blood-stage *P. vivax* vaccine candidate, Duffy binding protein region II
(DBPII). The experimental approach included retrospectively analyzing the relationship between the
long-term antibody response to DBPII-related antigens in the presence (or absence) of a sustained
response to EBV, as determined by the detection of circulating EBV DNA (EBV-DNAemia) or
EBV-specific antibody responses to the viral capsid antigen P18 (VCAp18) or EBV nuclear antigen
1 (EBNA1).

- 86
- 87

Material and methods

88

Area and study population

89 The study was carried out in the agricultural settlement of Rio Pardo (1°46'S—1°54'S, 60° 22'W-60°10'W), Presidente Figueiredo municipality, Northeast of Amazonas State in the 90 91 Brazilian Amazon region (Fig 1A). The study site and malaria transmission patterns were described 92 in detail elsewhere [16-18]. In this area, malaria transmission is considered hypo to mesoendemic, 93 and most residents were natives of the Amazon region. Inhabitants of the settlement live on 94 subsistence farming and fishing along the small streams. In the study area, P. vivax transmission is 95 predominant over P. falciparum (Fig 1B) and, since 2010, P. vivax has been responsible for all 96 clinical cases of malaria. Malaria transmission decreased drastically in recent years, and as of 2020, 97 no new clinical cases have been reported (Fig 1B).

98

99

Fig 1. Study site and methodological approach according to the temporal distribution of malaria cases during the 14-year follow up period (2008-2022). A) The study site, Rio Pardo settlement (dark green), in the Amazonas State (AM) of the Brazilian Amazon region (malariaendemic area, light green). B) Monthly-time series of malaria cases in the study area, including periods of high (I and III, light grey) and low (II and IV, dark grey) malaria transmission. Malaria cases (microscopy-positives) were reported by the Brazilian Epidemiological Surveillance System

It is made available under a CC-BY 4.0 International license .

5

for Malaria (SIVEP-Malaria), with *P. falciparum* (red) and *P. vivax* (blue) cases plotted per month.
C) Study design included nine cross-sectional surveys which were carried-out between 2008 and
2022. Number of participants enrolled per cross-sectional survey is shown inside the circles above
(cross-sectional, n), and number of eligible participants for the current study is inside the circles
below (eligible participants, n).

111

112 Study design and cross-sectional surveys

113 A population-based open cohort study was initiated in November 2008 and included three 114 cross-sectional surveys carried-out at six-month intervals (baseline, 6 and 12 months) as previously 115 reported [15, 16]. Briefly, (i) interviews were conducted through a structured questionnaire to obtain 116 demographical, epidemiological, and clinical data; (ii) physical examination, including body 117 temperature and spleen/liver size were recorded according to standard clinical protocols; (iii) venous blood was collected from individuals aged five years or older (EDTA, 5 mL); and (iv) 118 119 examination of Giemsa-stained thick blood smears for the presence of malaria parasites by light 120 microscopy. The geographical location of each dwelling was recorded using a hand-held 12-channel 121 global positioning system (GPS) (Garmin 12XL, Olathe, KS, USA) with a positional accuracy of 122 within 15m. Additional cross-sectional surveys were conducted during the 6th to 14th years of the 123 study, specifically on the following dates: October 6–13, 2014 (6th year), July 6–11, 2015 (7th 124 year), July 18–27, 2017 (9th year), August 4–16, 2019 (11th year), November 28–December 10, 125 2021 (13th year), and June 6–16, 2022 (14th year). During the long-term follow up study, the 126 number of malaria cases fluctuated in the study area, reflecting period of high (I and III) and low (II 127 and IV) malaria transmission (Fig 1B). The current study involved a retrospective approach, and the 128 methodological strategy was designed to include samples from all nine cross-sectional surveys 129 without any new recruitment involved. For this, а database (EpiData software; 130 http://www.epidata.dk) contained all individual information was accessed between June 27 of 2022 131 until July 30, 2024; in the database individual data were not linked to participants' identity as 132 participants were assessed by codes. The non-eligible criteria were (i) refusal to sign the informed

6

133 consent; (ii) young children (<5 years); (iii) pregnant women; (iv) any other morbidity that could be 134 traced; (iv) individuals who were unable to be recruited during at least two cross-sectional surveys, 135 (iv) individuals whose biological samples (DNA and plasma) were unavailable. A total of 272 136 individuals were eligible to the current study (Table 1), and they matched the original population for 137 age, sex, malaria exposure [17]. The number of eligible participants selected per cross-sectional surveys was included in the Fig 1C. 138

139

140 Table 1. Demographic and epidemiological data of participants at the time of enrollment

At enrollment (n=272)
35 (14-51)
1.12:1
143 (53%)
29 (15-48)
19 (12-21)

141

IQR, the Interquartile range

142

143 The ethical and methodological aspects of this study were approved by the Ethical 144 Committee of Research on Human Beings from the René Rachou Institute (CAAE: 145 96098618.9.0000.5091), according to the Resolutions of the Brazilian Council on Health (CNS-146 196/96 and CNS-466/2012). Formal written consent was obtained from all participants, either from 147 the participants themselves, their next of kin, caregivers, or guardians on behalf of child 148 participants. Data are separated from personal identifiers through use of a code.

149 The current study was conducted according to Laboratory biosafety and biosecurity policy 150 guidelines of the Oswaldo Cruz Foundation (FIOCRUZ, Ministry of Health, Brazil 151 (http://www.fiocruz.br/biosseguranca/Bis/manuais/biosseg_manuais.html).

152

Laboratory diagnosis of malaria 153

7

154 At the time of blood collection, all individuals were submitted to a finger-prick for malaria 155 diagnosis by light microscopy. The Giemsa-stained thick blood smears were prepared and examined 156 by experienced local microscopists, according to the malaria diagnosis guidelines of the Brazilian 157 Ministry of Health. Species-specific real-time PCR assay was conducted essentially as previously 158 described [19]. For this, genomic DNA was extracted from either whole blood samples collected in 159 EDTA, or from dried blood spots on filter paper using the Puregene blood core kit B (Qiagen, 160 Minneapolis, MN, USA) or the QIAmp DNA mini kit (Qiagen), respectively, according to 161 manufacturers' instructions.

162

163 **Recombinant blood stage** *P. vivax* proteins and IgG antibodies

164 detection

DBPII-related antigens. DBPII-Sal1, a recombinant Duffy binding protein region II 165 166 (DBPII) [20] including amino acids 243-573 of the Sal1 reference strain, and recombinant 167 DEKnull-2 [21], an engineered DBPII immunogen, were expressed as a 39kDa 6xHis fusion protein 168 and properly refolded, as previously described [21, 22]. Conventional Enzyme-Linked 169 Immunoassays (ELISA) for P. vivax IgG antibodies were carried out using P. vivax blood-stage 170 recombinant proteins as previously described [23], with serum samples at a dilution of 1:100. 171 Recombinant proteins were used at a final concentration of $3 \mu g/mL$. The results were expressed as 172 ELISA reactivity index (RI), calculated as the ratio of the mean optical density (OD at 492 nm) of 173 each sample to the mean OD plus three standard deviations of negative control plasma samples 174 from 30 individuals living in a nonendemic area of malaria (Belo Horizonte, Minas Gerais, Brazil) 175 and who have never been exposed to malaria transmission (unexposed volunteers). Values of RI > 1176 1.0 were considered seropositive.

177

178 **EBV DNA detection by real-time PCR**

179 The PCR primers for this assay were previously selected in the single-copy BALF-5 gene 180 encoding the viral DNA polymerase [24]; the upstream and downstream primer sequences were 50-181 CGGAAGCCCTCTGGACTTC-30 and 50-CCCTGTTTATCCGATGGAATG-30, respectively, with 182 a fluorogenic probe (50-TGTACACGCACGAGAAATGCGCC-30) with a sequence located 183 between the PCR primers. Detectable DNA from EBV was identified by a real-time PCR assay as 184 previously described [15]. Briefly, DNA from whole blood samples collected in EDTA was 185 extracted using Puregene blood core kit B (Qiagen, Minneapolis, MN, USA). The PCR reaction was 186 performed using a mixture containing 1µL of DNA, 0.2 µM each primer, 0.1 µM fluorogenic probe, 187 and 5 μ L of TaqMan Master Mix (PE Applied Biosystems), and the PCR cycle was performed as 188 follows: 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. The 189 TaqMan Master mix (PE Applied Biosystems) was used for all reactions. For all PCR analyses, 190 water was used as negative control, and DNA samples from individuals with history of 191 mononucleosis were used as positive control. Samples were defined as negative if the CT values 192 exceeded 40 cycles.

193

194

EBV antigens and serostatus

195 EBV-specific antibodies were detected using two synthetic peptides covering 196 immunodominant epitopes of the viral capsid antigen P18 (VCAp18 [BFRF3]) and EBV nuclear 197 antigen 1 (EBNA1 [BKRF1]) [25, 26]. Both synthetic peptides were provided by Dr. J. M. 198 Middeldorp (VU University Medical Center, Amsterdam, Netherland). For the assessment of the 199 levels of antibodies against lytic (VCAp18) and latent (EBNA1) EBV antigens, we used synthetic 200 peptide-based ELISA assays as previously described [15]. Briefly, each peptide was used at final 201 concentration of 1µg/mL with plasma samples diluted 1:100. IgG reactivities were determined using 202 commercial anti-human IgG secondary antibody conjugated to horseradish peroxidase (HRP) 203 (Sigma-Aldrich). For each experiment, plasma samples from subjects with or without a history of 204 mononucleosis infection who had previously been screened for the presence or absence of EBV-

9

specific antibodies were included as positive (EBV seropositive) or negative controls
(seronegative), respectively. All OD 450nm values were normalized by subtracting the value for
1:100-diluted EBV negative sera used in duplicate in each ELISA run. ELISA's cutoffs were
previously established as [15]: (i) 0.38 for VCA IgG (82% sensitivity; 83% specificity), (ii) 0.20 for
EBNA1 IgG (75% sensitivity; 100% specificity).

210

211 Statistical analysis

A database was created using EpiData software (http://www.epidata.dk). The graphics and the statistical analyses were performed using GraphPad Prism version 9.5.0 - GraphPad Software (La Jolla, California, USA) and Stata software version 12.0 - Stata Corp (College Station, Texas, USA).

216 The Shapiro-Wilk test was performed to evaluate normality of variables. For the statistical 217 analyses, the antibody response was defined either as a continuous variable (the levels of antibody 218 response) or as a binary categorical variable (proportion of seropositive individuals); differences 219 between medians were tested by Mann-Whitney test or Kruskal-Wallis as appropriate; differences 220 in proportions were evaluated by chi-square test or Fisher's exact test, as appropriated. Spearman's 221 correlation matrices were used to nonparametric measure of rank correlation. For statistical 222 purposes, the amount of time participants contributed to this open cohort study was estimated in 223 persons-month, with the sum of total time contributed by all subjects (months) used to calculate the 224 incidence densities of the events of interest. Kaplan-Meier curves of survival were used to estimate 225 the probability of remaining seropositive for *P. vivax* as function of the profile of EBV infection 226 (serostatus and EBV-DNAemia). For that, the average duration of seropositivity over the 14th-years 227 period was defined when 50% of responders lost their antibodies. Logistical regression models were 228 constructed to investigate P. vivax antibodies clearance (rates adjusted per 100 persons-month) 229 according to the profile of EBV infections, with the relative risk (95% CI) of losing P. vivax

10

antibody response estimated according to the first seronegative episode. For all analyses, an alphaerror of 0.05 was considered.

232

233 **Results**

234 Plasmodium vivax infections and circulating EBV DNA during

235 the follow-up

236 In this long-term follow-up study, malaria blood-stage infections varied significantly, but 237 with a predominance of sub-patent (PCR-positive) over patent (microscopy-positive) infections (Fig 238 2A). All malaria infections detected by microscopy were identified as *P. vivax* mono-infections, 239 with all but one (11 of 12) detected during the first year of the follow-up (Period I). Submicroscopic 240 malaria infections were also predominant in the first year of follow-up, with frequency ranging 241 from 9 to 22% (Fig 2A). In subsequent cross-sectional surveys, lower frequencies of PCR-positive 242 samples were detected (3-4% and 4-6% during periods II and III, respectively), with no cases of 243 malaria detected at the end of the study (IV) (Fig 2A). Considering all malaria cases detected during 244 the study (n=113), there was a predominance of *P. vivax* mono-infection, accounting for 76% 245 (n=86) of the total malaria infections, compared to 12% (n=14) of P. falciparum, and 12% (n=13) of 246 mixed infections by these two *Plasmodium* species (S1 Fig).

247

248

249 Fig 2. Malaria infections and EBV-DNAemia during the follow-up-period. A) Frequencies of 250 malaria positive samples detected by microscopy (red bars) or species-specific PCR-based protocol 251 (light pink bars) and B) Frequencies of circulating EBV DNA (EBV-DNAemia) detected by virus-252 specific PCR-based protocol (lilac bars). Each bar represents a cross-sectional survey, with dashed 253 lines representing the periods of high (I and III) and low (II and IV) malaria transmission, as 254 described in the legend of Fig 1B. C) A comparison between the proportion of malaria infections 255 and EBV-DNAemia over time. D) Representation of a Spearman correlation coefficient, in which 256 each dot represents the intersection between the frequency of malaria infections and detectable

11

EBV-DNAemia by cross-sectional survey. Numbers at the bottom of each bar (A, B) represent the number of participants per survey (n survey) and the total number of participants per period (n period).

260

261

262 On the first period of follow-up, the proportion of individuals who had circulating viral 263 DNA (EBV-DNAemia) ranged from 28 to 37% (Fig 2B). After that, EBV-DNAemia episodes 264 decreased substantially (Fig 1C), except for the beginning of period III (9-years of the follow-up), a 265 time of high malaria transmission in the study area (Fig 1B). It is noteworthy that the lowest 266 frequencies of EBV DNA positivity were found during the II (11 to 14%) and IV (2 to 3%) periods 267 of the study (Fig 2B), corresponding to periods of lowest malaria transmission in the area (Fig 1B). 268 In the study population, episodes of EBV-DNAemia were transiently detected in most individuals, 269 which excluded the possibility of categorizing individuals as having long-term persistent EBV-270 DNAemia. Only seven out of 272 individuals had long-term EBV-DNAemia (positive samples from 271 baseline to at least the II period); four of them (343, 272, 179, 276) had malaria infections at some 272 point in the study (S1 Fig). During the follow-up, a strong positive association was detected 273 between malaria infections and EBV-DNAemia (r = 0.7269; p = 0.0035) (Fig 2D). Similar results 274 were found when only *P. vivax* monoinfections were analyzed (r = 0.6522; p = 0.0085, data not 275 shown).

276

277 Episodes of EBV-DNAemia and longevity of naturally acquired antibodies

278 against *Plasmodium vivax*

In the study population, the profile of antibody response to DBPII-based antigens decreased over time, with a more prolonged response to DEKnull-2 in period II (low transmission) as compared with DBPII (Sal1) (S2 Fig); at the same time, the levels of anti-DBPII antibodies were lower than anti-DEKnull-2. To further evaluate whether episodes of EBV-DNAemia (none, one, or multiple) could influence the persistence of strain-specific (Sal1) or strain-transcending (DEKnull-

12

284 2) DBPII antibody repertoire, Kaplan-Meier's survival curves were constructed. In general, the 285 results demonstrated that the persistence of antibody responses to either DBPII-Sal1 or DEKnull-2 286 was similar between individuals who had none, one or multiple episodes of EBV-DNAemia (Fig 3). 287 More specifically, considering the subgroups of DBPII-Sal1 responders, the average time in which 288 50% of responders lost their antibody response ranges from 156 to 168 months (S1 Table). The 289 average time for DEKnull-2 subgroups to lose antibody response was estimated as 168 months. In 290 addition, antibody clearance rates (adjusted per 100 persons-month) were similar between 291 subgroups of DBPII-Sal1 (0.48 to 0.57) and DEKnull-2 (0.27 to 0.46) (S1Table).

292

293

294 Fig 3. Maintenance of *P. vivax* antibody response over time according to episodes of EBV-295 **DNAemia** (none, one or multiple). The Kaplan-Meier's curves show the cumulative survival 296 probabilities of maintaining an antibody response against (A) DBPII-Sal1 and (B) DEKnull-2 297 among responders who were stratified according to the presence or absence of detectable EBV-298 DNAemia. Each line represents the survival probability of antibodies over time among (i) 299 individuals who did not have detectable EBV DNA episodes during the 14-years follow-up (dashed 300 line); (ii) individuals who had a single EBV DNA episode (lilac line); and (iii) individuals who had 301 more than one (multiple) EBV DNA episodes (purple line). Number of individuals and contribution 302 time (persons/month) of each group were described in S1 Table.

303

304

305 EBV serostatus and long-term *P. vivax* antibody response

To evaluate the EBV serological status of the study population, the presence and levels of IgG antibodies to EBV antigens associated with lytic (VCAp18) or latent (EBNA1) phases of infection were investigated. As expected for a predominantly adult population, responders' frequencies were high (> 60%) for both viral proteins and it remained relatively stable until the end of the follow-up (S3 Fig). In general, IgG-VCAp18 levels were higher compared to IgG-EBNA1.

13

Spearman correlation analyses were performed to investigate whether the levels of EBV antibodies correlated with *P. vivax*-specific antibodies. Regardless of the malaria transmission period (high, I/III or low, II/IV), the results demonstrated that anti-EBV antibodies (VCAp18 and EBNA1) did not correlate with anti-*P. vivax* antibodies (DBPII-Sal1 and DEKnull-2) (Fig 4). Despite of that, the antibody responses to DBPII-Sal1 and DEKnull-2 were strongly correlated (r=0.71 to 0.82; p<0,0001 for all periods). In general, antibodies to VCAp18 and EBNA1 presented a weak but positive correlation (except for period IV).

318

319

Fig 4. Correlation between IgG antibody levels to *Plasmodium vivax* and EBV virus over time. Clustering was based on the Spearman correlation coefficient for assays measuring specific EBV antibodies (VCAp18 and EBNA1) and specific *P. vivax* antibodies (DBPII-Sal1 and DEKnull-2). Matrix heatmaps were illustrated for each study period (I, II, III and IV). Positive correlations are shown in blue and negative correlations are shown in red. The asterisks represent statistically significant differences (*p < 0,05; **p < 0,01; *** p < 0,001).

326

To determine whether EBV serological status could influence the long-term antibody response to DBPII-based antigens, IgG-VCAp18 and IgG-EBNA1 carriers were stratified as persistent (PR), temporary (TR) or non-responder (NR). Survival curves of antibodies allowed to demonstrate that the decline over time of responders to both DBPII-based antigens were similar between PR, TR or NR for either VCAp18 (Figs 5A and 5B) or EBNA1 (Figs 5C and 5D). Despite that, antibody clearance rates for DEKnull-2 responders (0.26 to 0.36 per 100 persons-month) declined more slowly than from DBPII-Sal1 (0.45 to 0.53 per 100 persons-months) (S1 Table).

334

335

Fig 5. Maintenance of *P. vivax* antibody response over time according to EBV serostatus (persistent-PR, temporary-TR, and non-responder-NR). The Kaplan-Meier's curves show the cumulative survival probabilities of maintaining an antibody response against (A, C) DBPII-Sall and (B, D) DEKnull-2 among responders who were stratified according to the response profile for

VCAp18 or EBNA1. Each line represents the survival probability of antibodies over time among (i)
persistent responders, who had IgG response over the 14 years of follow-up (A and B - brown line;
C and D - red line); (ii) temporary responders, who had variable IgG response during crosssectional surveys (A and B - yellow line; C and D - pink line); and (iii) non-responders, who had no
IgG response detected any time in the study (dashed line). Number of individuals and contribution
time (person/month) of each group are described in S1 Table.

- 346
- 347

348 **Discussion**

This 14-year follow-up study provided for the first time an exploratory description of the long-term *P. vivax* humoral immune response in the context of EBV co-infection. For this, immunogens based on the DBPII were used, including a common DBPII variant (Sal1) circulating in the Amazon area [16] and the engineered DEKnull-2 that has been associated with stronger, broader, and long-term neutralizing antibody response in the study area [18, 21].

354 In the study population, it was essential to identify viral DNA carriers, as circulating EBV 355 DNA could be an indicator of active EBV replication [27]. In this P. vivax semi-immune adults, the 356 detection of EBV DNA in peripheral blood decreased significantly over the years, precluding any 357 attempts to classify individuals as long-term DNAemia carriers. The detection of viral DNA of most 358 carriers did not persist over the first few months of the study, which may reflect that once infected 359 by EBV early on, the subjects - in general - have good immunological control over EBV (reflected 360 here by stable antibody responses to VCAp18 and EBNA1). Concomitantly, acute malaria infection 361 (presence of parasites and/or P. vivax DNA in the peripheral blood) also decreased over time, which 362 led to a positive association between the presence of acute *P. vivax* infection and EBV-DNAemia. 363 At this point, it is not possible to determine whether this potential association represents a spurious 364 correlation or may reflect an influence of concurrent P. vivax parasite in the activation of EBV 365 replication cycle, as it has been proposed in the case of the more lethal malaria parasite, P. 366 falciparum [28]. In Indonesia, where P. falciparum and P. vivax species are co-endemic at

15

367 substantial proportions, it was demonstrated that EBV DNA levels were significantly elevated in 368 both P. falciparum and P. vivax mono-infections as compared with uninfected controls, suggesting 369 cytokine-mediated imbalance of immune control of EBV during active malaria [29]. Although the 370 study from Indonesia supports our findings, the influence of concomitant transmission of P. 371 falciparum cannot be ruled out in that area, especially because PCR-based protocols were not used 372 to investigate submicroscopic infections. In the case of P. falciparum – whose relationship with 373 EBV infections is involved in the genesis of endemic Burkitt lymphoma (eBL) [30] – it was 374 demonstrated that repeated malaria infections were associated with increased proliferation and 375 transformation of EBV-infected cells [31]. Also, the clearance of circulating EBV after P. 376 falciparum antimalarial treatment suggests a direct relationship between active malaria infection 377 and viral reactivation [28]. Of note, however, the aggressive eBL childhood cancer seems to be 378 exclusively linked to *P. falciparum* exposure, but not to other human malaria parasites [32]. 379 Because of this, the direct relationship between active *P. vivax* infection and viral reactivation needs 380 further confirmation.

381 We further analyzed whether one or more episodes of viral DNAemia, at any time of the 382 long-term follow-up period, could impact the persistence of *P. vivax*-specific antibody responses. 383 Regardless of viral DNA carriers' status, maintenance over time of antibody responses to either 384 DBPII-Sal1 or DEKnull-2 was similar between individuals who had no, one or multiple episodes of 385 EBV-DNAemia; for example, the average time for the loss of antibody response was 168 months 386 for DEKnull-2 and from 156 to 168 months for DBPII-Sal1. In our previous case-control study, 387 lower IgG reactivity to *P. vivax* antigens was detected in the group of persistent EBV DNA carriers 388 (cases) compared to age-matched controls (no circulant viral DNA) [15]. Unfortunately, differences 389 in the study design and the absence of a subset of persistent viral DNA carriers in the current study 390 preclude a direct comparison with the previous result. Despite this, it must be noted that, in the 391 present study, the frequencies of both malaria infection and circulating viral DNA progressively 392 decreased over time, making it reasonable to speculate that this may have masked a possible

16

influence of active EBV replication on the long-term *P. vivax* immune response. To properly address
this topic, it would be of relevance to examine *P. vivax*-exposed children, as typically the EBV
primary infection occurs during childhood, with an early EBV seroconversion in Latin American
populations associated with low socioeconomic status [33].

397 To address whether EBV serostatus could influence acquired *P. vivax* antibody responses, 398 individuals were further categorized as persistent (PR), temporary (TR), or non-responder (NR) for 399 lytic (VCAp18) or latent (EBNA1) viral antigens. Although antibody clearance rates were faster for 400 Sal-1 (0.49 to 0.55/100 persons-month) than for DEKnull-2 (0.27 to 0.37/100 persons-month), the 401 results of the 14-year follow-up study demonstrated that probabilities of maintaining antibodies to 402 DBPII-based antigens were similar for IgG-VCAp18 or IgG-EBNA1 subgroups (PR, TR, or NR). It 403 is noteworthy that no association (positive or negative) was detected between the levels of anti-EBV 404 antibodies and anti-P. vivax antibodies. Together, these results suggested that sustained EBV 405 antibody responses to lytic/latent viral antigens did not impair the long-term antibody response to 406 DBPII-related antigens, including both strain-specific (Sal1) and strain-transcending (DEKnull-2) 407 immune responses.

408 Our study has limitations that should be considered when interpreting the results. First, a 409 progressive decrease in malaria transmission over time precluded more robust statistical analysis to 410 confirm the association between acute *P. vivax* infection and EBV-DNAemia. To explore whether 411 concurrent P. vivax infection may result in EBV lytic replication, perhaps it should be more 412 appropriate to evaluate the levels of viral DNA methylation, as unmethylated viral DNA occurs 413 when EBV switches to the lytic phase and in virions [34]; nevertheless, the investigation of this 414 topic was outside of the scope of the current study. Secondly, the EBV serostatus of the study 415 population was constrained to the profile of IgG antibodies to VCAp18 (lytic) and EBNA1 (latent) 416 antigens. Due to the limitations of plasma samples available over the 14 years of study, we chose 417 the lytic antigen VCAp18, because from a panel of synthetic peptides targeting the most frequent 418 EBV lytic antigens (i.e., IgG/IgM to VCAp18, IgM to ZEBRA and IgM EAd-p45/52), only the

419 levels of anti-IgG VCAp18 showed a positive association with EBV DNA copies in the peripheral 420 blood of Amazonian adults [15]. Notwithstanding these limitations, we are confident that, in this 421 immunocompetent adult population, the assessment of VCAp18-IgG and EBNA1-IgG represented 422 the best combination for long-term sero-detection of anti-EBV antibodies. Finally, as EBV latency 423 establishment is in B cells [35], it should be of interest to investigate whether *P. vivax*-specific 424 memory B cells are compromised during EBV reactivation.

In conclusion, in this 14-year follow-up study we demonstrate that, in an immunocompetent *P. vivax*-exposed adult population, neither sporadic episodes of circulating EBV DNA nor a sustained antibody response to lytic/latent EBV antigens influence the longevity of both strainspecific and strain-transcending DBPII immune responses. Future studies should investigate a possible association between the presence of acute *P. vivax* infection and EBV-DNAemia.

430

431 **Acknowledgments**

432 We thank the inhabitants of Rio Pardo for enthusiastic participation in the study; the local 433 malaria control team in Presidente Figueiredo for their logistic support; the Instituto Leônidas &. 434 Maria Deane – Fiocruz-Amazônia and Fundação de Medicina Tropical Dr. Heitor Vieira Dourado 435 for local support, and the Instituto René Rachou – Fiocruz-Minas, Belo Horizonte, MG, for overall 436 support. LHC, FSK, and CFJF are research fellows from CNPq. Scholarship was sponsored by 437 FAPEMIG (BAR), CAPES (LFFG and SLA) and the Fiocruz Innovation Support Initiative/Inova-438 Fiocruz (MFAN). We also thank the financial support from the Program for Institutional 439 Internationalization of the Higher Education Institutions and Research Institutions of Brazil-440 CAPES-PrInt from FIOCRUZ. The authors thank the Network Technological Platforms from 441 FIOCRUZ, for the support and financing of the services provided by Digital and Real-Time PCR 442 Facility from René Rachou Institute - FIOCRUZ MG - RPT09D.

443

444 **References**

18

445

Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, et al. Mapping the
 global prevalence, incidence, and mortality of Plasmodium falciparum, 2000-17: a spatial and
 temporal modelling study. Lancet. 2019;394(10195):322-31. Epub 20190619. doi: 10.1016/S0140 6736(19)31097-9. PubMed PMID: 31229234; PubMed Central PMCID: PMCPMC6675740.

Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the
 global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal
 modelling study. Lancet. 2019;394(10195):332-43. Epub 20190619. doi: 10.1016/S0140 6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736.

Fernandez-Becerra C, Aparici-Herraiz I, Del Portillo HA. Cryptic erythrocytic infections in
 Plasmodium vivax, another challenge to its elimination. Parasitol Int. 2022;87:102527. Epub
 20211209. doi: 10.1016/j.parint.2021.102527. PubMed PMID: 34896615.

457 4. Anstey NM, Tham WH, Shanks GD, Poespoprodjo JR, Russell BM, Kho S. The biology and
458 pathogenesis of vivax malaria. Trends Parasitol. 2024;40(7):573-90. Epub 20240515. doi:
459 10.1016/j.pt.2024.04.015. PubMed PMID: 38749866.

460 5. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of
461 the Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. Epub 20200422. doi:
462 10.1016/j.pt.2020.03.009. PubMed PMID: 32407682; PubMed Central PMCID:
463 PMCPMC7297627.

Mendonca VR, Andrade BB, Souza LC, Magalhaes BM, Mourao MP, Lacerda MV, et al.
Unravelling the patterns of host immune responses in Plasmodium vivax malaria and dengue coinfection. Malar J. 2015;14:315. Epub 20150814. doi: 10.1186/s12936-015-0835-8. PubMed PMID:
26271921; PubMed Central PMCID: PMCPMC4536664.

Rattanapunya S, Kuesap J, Chaijaroenkul W, Rueangweerayut R, Na-Bangchang K.
Prevalence of malaria and HIV coinfection and influence of HIV infection on malaria disease
severity in population residing in malaria endemic area along the Thai-Myanmar border. Acta Trop.
2015;145:55-60. Epub 20150226. doi: 10.1016/j.actatropica.2015.02.001. PubMed PMID:
25728746.

473 8. Hussein R, Guedes M, Ibraheim N, Ali MM, El-Tahir A, Allam N, et al. Impact of COVID474 19 and malaria coinfection on clinical outcomes: a retrospective cohort study. Clin Microbiol Infect.

19

475 2022;28(8):1152 e1- e6. Epub 20220331. doi: 10.1016/j.cmi.2022.03.028. PubMed PMID:
476 35367364; PubMed Central PMCID: PMCPMC8968160.

Forero-Pena DA, Carrion-Nessi FS, Omana-Avila OD, Mendoza-Millan DL, Romero SR,
Escalante-Perez IA, et al. Plasmodium vivax and SARS-CoV-2 co-infection in Venezuela: A case
series from the malaria hotspot in Latin America. Travel Med Infect Dis. 2022;50:102460. Epub
20220914. doi: 10.1016/j.tmaid.2022.102460. PubMed PMID: 36115526; PubMed Central PMCID:
PMCPMC9473143.

482 10. Guerra CVC, da Silva BM, Muller P, Baia-da-Silva DC, Moura MAS, Araujo JDA, et al.
483 HIV infection increases the risk of acquiring Plasmodium vivax malaria: a 4-year cohort study in
484 the Brazilian Amazon HIV and risk of vivax malaria. Sci Rep. 2022;12(1):9076. Epub 20220531.
485 doi: 10.1038/s41598-022-13256-4. PubMed PMID: 35641592; PubMed Central PMCID:
486 PMCPMC9156757.

487 11. Forero-Pena DA, Carrion-Nessi FS, Lopez-Perez M, Sandoval-de Mora M, Amaya ID, 488 Gamardo AF, et al. Seroprevalence of viral and bacterial pathogens among malaria patients in an 489 endemic area of southern Venezuela. Infect Dis Poverty. 2023;12(1):33. Epub 20230410. doi: 490 10.1186/s40249-023-01089-w. PubMed PMID: 37038195; PubMed Central PMCID: 491 PMCPMC10084699.

492 12. da Veiga GTS, Moriggi MR, Vettorazzi JF, Muller-Santos M, Albrecht L. Plasmodium vivax
493 vaccine: What is the best way to go? Front Immunol. 2022;13:910236. Epub 20230116. doi:
494 10.3389/fimmu.2022.910236. PubMed PMID: 36726991; PubMed Central PMCID:
495 PMCPMC9885200.

496 13. Matar CG, Jacobs NT, Speck SH, Lamb TJ, Moormann AM. Does EBV alter the
497 pathogenesis of malaria? Parasite Immunol. 2015;37(9):433-45. Epub 2015/06/30. doi:
498 10.1111/pim.12212. PubMed PMID: 26121587.

499 14. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol.
500 2001;1(1):75-82. doi: 10.1038/35095584. PubMed PMID: 11905817.

501 15. Dias MHF, Guimaraes LFF, Barcelos MG, Moreira EUM, do Nascimento MFA, de Souza 502 TN, et al. Impact of Epstein-Barr virus co-infection on natural acquired Plasmodium vivax antibody 503 response. PLoS Negl Trop Dis. 2022;16(8):e0010305. Epub 20220803. doi: 504 10.1371/journal.pntd.0010305. PubMed PMID: 35921373; PubMed Central PMCID: 505 PMCPMC9377613.

It is made available under a CC-BY 4.0 International license .

20

Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, et al. Plasmodium vivax
Duffy binding protein: baseline antibody responses and parasite polymorphisms in a wellconsolidated settlement of the Amazon Region. Trop Med Int Health. 2012;17(8):989-1000. Epub
2012/05/31. doi: 10.1111/j.1365-3156.2012.03016.x. PubMed PMID: 22643072.

510 17. Kano FS, Souza-Silva FA, Torres LM, Lima BA, Sousa TN, Alves JR, et al. The Presence,
511 Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies
512 Are Influenced by HLA Class II Allelic Variants. PLoS Negl Trop Dis. 2016;10(12):e0005177.
513 Epub 2016/12/14. doi: 10.1371/journal.pntd.0005177. PubMed PMID: 27959918; PubMed Central
514 PMCID: PMCPMC5154503.

Medeiros CMP, Moreira EUM, Pires CV, Torres LM, Guimaraes LFF, Alves JRS, et al.
Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II
immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.
PLoS One. 2020;15(5):e0232786. Epub 2020/05/08. doi: 10.1371/journal.pone.0232786. PubMed
PMID: 32379804; PubMed Central PMCID: PMCPMC7205269.

Amaral LC, Robortella DR, Guimaraes LFF, Limongi JE, Fontes CJF, Pereira DB, et al.
Ribosomal and non-ribosomal PCR targets for the detection of low-density and mixed malaria
infections. Malar J. 2019;18(1):154. Epub 2019/05/02. doi: 10.1186/s12936-019-2781-3. PubMed
PMID: 31039781; PubMed Central PMCID: PMCPMC6492410.

524 20. Fang XD, Kaslow DC, Adams JH, Miller LH. Cloning of the Plasmodium vivax Duffy
525 receptor. Mol Biochem Parasitol. 1991;44(1):125-32. Epub 1991/01/01. doi: 10.1016/0166526 6851(91)90228-x. PubMed PMID: 1849231.

Ntumngia FB, Pires CV, Barnes SJ, George MT, Thomson-Luque R, Kano FS, et al. An
engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly
neutralizing antibodies. Sci Rep. 2017;7(1):13779. Epub 2017/10/25. doi: 10.1038/s41598-01713891-2. PubMed PMID: 29062081; PubMed Central PMCID: PMCPMC5653783.

531 22. Ntumngia FB, Adams JH. Design and immunogenicity of a novel synthetic antigen based on
532 the ligand domain of the Plasmodium vivax duffy binding protein. Clin Vaccine Immunol.
533 2012;19(1):30-6. Epub 2011/11/26. doi: 10.1128/CVI.05466-11. PubMed PMID: 22116684;
534 PubMed Central PMCID: PMCPMC3255949.

535 23. Pires CV, Alves JRS, Lima BAS, Paula RB, Costa HL, Torres LM, et al. Blood-stage
536 Plasmodium vivax antibody dynamics in a low transmission setting: A nine year follow-up study in

21

537 2018/11/13. the Amazon region. PLoS One. 2018;13(11):e0207244. Epub doi: 538 10.1371/journal.pone.0207244. PubMed PMID: 30419071; PubMed Central PMCID: 539 PMCPMC6231651.

540 24. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative
541 analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol.
542 1999;37(1):132-6. Epub 1998/12/17. doi: 10.1128/JCM.37.1.132-136.1999. PubMed PMID:
543 9854077; PubMed Central PMCID: PMCPMC84187.

544 25. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single545 assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived
546 synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera
547 from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol.
548 2006;44(4):1459-67. Epub 2006/04/07. doi: 10.1128/JCM.44.4.1459-1467.2006. PubMed PMID:
549 16597877; PubMed Central PMCID: PMCPMC1448657.

26. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, et al.
Serological evidence for long-term Epstein-Barr virus reactivation in children living in a
holoendemic malaria region of Kenya. J Med Virol. 2009;81(6):1088-93. Epub 2009/04/22. doi:
10.1002/jmv.21485. PubMed PMID: 19382256; PubMed Central PMCID: PMCPMC3134942.

Rasti N, Falk KI, Donati D, Gyan BA, Goka BQ, Troye-Blomberg M, et al. Circulating
epstein-barr virus in children living in malaria-endemic areas. Scand J Immunol. 2005;61(5):461-5.
doi: 10.1111/j.1365-3083.2005.01589.x. PubMed PMID: 15882438.

Donati D, Espmark E, Kironde F, Mbidde EK, Kamya M, Lundkvist A, et al. Clearance of
circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J
Infect Dis. 2006;193(7):971-7. Epub 20060301. doi: 10.1086/500839. PubMed PMID: 16518759.

560 29. Budiningsih I, Dachlan YP, Hadi U, Middeldorp JM. Quantitative cytokine level of TNF-561 alpha, IFN-gamma, IL-10, TGF-beta and circulating Epstein-Barr virus DNA load in individuals 562 with acute Malaria due to P. falciparum or P. vivax or double infection in a Malaria endemic region 563 in Indonesia. PLoS One. 2021;16(12):e0261923. Epub 20211228. doi: 564 10.1371/journal.pone.0261923. PubMed PMID: 34962938; PubMed Central PMCID: 565 PMCPMC8714090.

566 30. Moormann AM, Bailey JA. Malaria - how this parasitic infection aids and abets EBV-567 associated Burkitt lymphomagenesis. Curr Opin Virol. 2016;20:78-84. Epub 2016/10/01. doi:

568 10.1016/j.coviro.2016.09.006. PubMed PMID: 27689909; PubMed Central PMCID:
569 PMCPMC5102755.

Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, et al.
Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect
Dis. 2005;191(8):1233-8. Epub 2005/03/19. doi: 10.1086/428910. PubMed PMID: 15776368.

32. Quintana MDP, Smith-Togobo C, Moormann A, Hviid L. Endemic Burkitt lymphoma - an
aggressive childhood cancer linked to Plasmodium falciparum exposure, but not to exposure to
other malaria parasites. APMIS. 2020;128(2):129-35. Epub 2020/03/07. doi: 10.1111/apm.13018.
PubMed PMID: 32133709.

S77 33. Chabay P, Lens D, Hassan R, Rodriguez Pinilla SM, Valvert Gamboa F, Rivera I, et al.
Lymphotropic Viruses EBV, KSHV and HTLV in Latin America: Epidemiology and Associated
Malignancies. A Literature-Based Study by the RIAL-CYTED. Cancers (Basel). 2020;12(8). Epub
20200804. doi: 10.3390/cancers12082166. PubMed PMID: 32759793; PubMed Central PMCID:
PMCPMC7464376.

582 34. Guo R, Gewurz BE. Epigenetic control of the Epstein-Barr lifecycle. Curr Opin Virol.
583 2022;52:78-88. Epub 20211208. doi: 10.1016/j.coviro.2021.11.013. PubMed PMID: 34891084;
584 PubMed Central PMCID: PMCPMC9112224.

585 35. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr 586 Virol. virus persistent infection. Curr Opin 2013;3(3):227-32. Epub 20130515. doi: 587 PMID: PubMed 10.1016/j.coviro.2013.04.005. PubMed 23683686; Central PMCID: 588 PMCPMC3789532.

589

590

591 Supporting information

592 S1 Fig. Malaria infections in 77 eligible participants screened for the presence of circulanting

593 EBV DNA during the follow-up study. P. vivax infections are represented in red, P. falciparum in

594 yellow, mixed infections (*P. falciparum* plus *P. vivax*) in orange, and uninfected samples in white.

- 595 During the cross-sectional surveys, the presence or absence of episodes of EBV-DNAemia are
- 596 represented in purple and white circles, respectively.

22

5	a	7
J	2	1

598 S2 Fig. Dynamics of naturally acquired antibody responses to P. vivax DBPII-based antigens 599 during the follow-up study. (A) Frequencies and (B) levels of antibodies against DBPII-Sal1 and 600 DEKnull-2, as determined by conventional serological assays (ELISA). Results were expressed as 601 reactivity index (RI), with RI >1.0 considered as an ELISA-positive response. In B, black lines 602 inside the violin plot represent the median RI, with light green and blue lines representing the 603 interquartile range. 604 605 S3 Fig. Dynamic of antibody responses to EBV peptides during the 14 years follow-up study. 606 (A) Frequencies and (B) levels of antibodies against VCAp18 and EBNA1, as determined by 607 conventional serological assays (ELISA). Results were expressed as the optical density at 450 nm 608 (OD450), with OD >0.37 and >0.20 considered as ELISA-positive responses to VCAp18 and 609 EBNA1, respectively. In B, black lines inside the violin plot represent the median RI, with yellow 610 and pink lines representing the interquartile range. 611 612 S1 Table. DBPII-related antibody responses over time based on the presence or absence of 613 **EBV-DNAemia**. 614 615 S2 Table. DBPII-related antibody responses over time based on the antibody response profile 616 against EBV peptides

617